The Effects of Empagliflozin on Renal Outcomes in Post Severe Acute Kidney Injury Survivors

Chulalongkorn University

Status and phase: Active, not recruiting; Phase 1

Conditions: Empagliflozin in Post AKI Stage 2-3

Treatments: Drug: Empagliflozin 10 MG; Drug: Placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT05360615

IRB.211/65

Details and patient eligibility

About

Effects of Empagliflozin compared with placebo in post severe acute kidney injury survivors, evaluated by MAKE365.

Enrollment: 147 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• post AKI stage 2-3
• CrCl > 20

Exclusion criteria

• pregnancy
• post kidney transplant
• previous use of SGLT2 Inhibitors
• history of ketoacidosis

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

147 participants in 2 patient groups, including a placebo group

Empagliflozin

Experimental group

Treatment:

Drug: Empagliflozin 10 MG

Placebo

Placebo Comparator group

Treatment:

Drug: Placebo